Wu et al. discovered that rhubarb-free anthraquinones (RFAs) might be a potential therapeutic agent for MASLD, since they directly inhibited the assembly of NLRP3 in vitro, but not NLRP3 protein expression, and improved histopathological inflammation in MASLD in mice fed a methionine and choline deficient diet [53]. Here, NLRP3 is linked to metabolic dysfunction-associated steatotic liver disease.